WC
GILD icon

Westerkirk Capital’s Gilead Sciences GILD Stock Holding History

Westerkirk Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$723K Hold
5,186
– – 0.08% 123
2025
Q4 		$637K Sell
5,186
-425
-8% -$51.6K 0.06% 135
2025
Q3 		$623K Hold
5,611
– – 0.07% 177
2025
Q2 		$622K Buy
+5,611
New +$597K 0.08% 174

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Westerkirk Capital's GILD Position: Q1 2026 in Review

Westerkirk Capital held its Gilead Sciences (GILD) position steady in Q1 2026 at 5,186 shares worth $723K. The position accounts for 0.08% of the portfolio, ranked #123.

Westerkirk Capital first reported a position in GILD in Q2 2025 and has held it in 4 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Westerkirk Capital held 5,186 shares of Gilead Sciences worth $723K as of Q1 2026.
  • Westerkirk Capital left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.08% of Westerkirk Capital's portfolio in Q1 2026, its #123 holding.
  • Westerkirk Capital first reported a position in Gilead Sciences in Q2 2025 and has held it in 4 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Westerkirk Capital's 13F filing for Q1 2026, filed 14 May 2026.